CA2843875A1 - Promedicaments lies a des excipients hydrosolubles de forte charge - Google Patents
Promedicaments lies a des excipients hydrosolubles de forte charge Download PDFInfo
- Publication number
- CA2843875A1 CA2843875A1 CA2843875A CA2843875A CA2843875A1 CA 2843875 A1 CA2843875 A1 CA 2843875A1 CA 2843875 A CA2843875 A CA 2843875A CA 2843875 A CA2843875 A CA 2843875A CA 2843875 A1 CA2843875 A1 CA 2843875A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- hydrochloride
- formula
- moiety
- diaminobutyric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177405 | 2011-08-12 | ||
| EP11177405.5 | 2011-08-12 | ||
| PCT/EP2012/065731 WO2013024047A1 (fr) | 2011-08-12 | 2012-08-10 | Promédicaments liés à des excipients hydrosolubles de forte charge |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2843875A1 true CA2843875A1 (fr) | 2013-02-21 |
| CA2843875C CA2843875C (fr) | 2020-01-07 |
Family
ID=46690492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2843875A Active CA2843875C (fr) | 2011-08-12 | 2012-08-10 | Promedicaments lies a des excipients hydrosolubles de forte charge |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140296257A1 (fr) |
| EP (1) | EP2741779A1 (fr) |
| AU (1) | AU2012296949B2 (fr) |
| CA (1) | CA2843875C (fr) |
| HK (1) | HK1198629A1 (fr) |
| WO (1) | WO2013024047A1 (fr) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2978909T3 (es) | 2012-08-21 | 2024-09-23 | Janssen Pharmaceutica Nv | Anticuerpos contra haptenos de aripiprazol y uso de los mismos |
| CN107043424B (zh) | 2012-08-21 | 2021-03-16 | 詹森药业有限公司 | 利培酮的抗体及其用途 |
| HK1211958A1 (en) | 2012-08-21 | 2016-06-03 | Ortho-Clinical Diagnostics, Inc. | Antibodies to paliperidone and use thereof |
| CA2882562C (fr) | 2012-08-21 | 2019-08-27 | Eric Hryhorenko | Anticorps diriges contre l'aripiprazole et leur utilisation |
| TR201911272T4 (tr) | 2012-08-21 | 2019-08-21 | Janssen Pharmaceutica Nv | Paliperidon haptenleri. |
| CN104736566A (zh) | 2012-08-21 | 2015-06-24 | 奥索临床诊断有限公司 | 帕潘立酮半抗原的抗体及其用途 |
| EP3321254B1 (fr) | 2012-08-21 | 2020-08-12 | Janssen Pharmaceutica NV | Haptènes d'aripiprazole et leur utilisation dans des dosages immunologiques |
| EP2888284B1 (fr) | 2012-08-21 | 2022-07-06 | Janssen Pharmaceutica NV | Anticorps dirigés contre des haptènes de rispéridone et leur utilisation |
| CA2891949C (fr) | 2012-12-07 | 2021-03-23 | Ascendis Pharma A/S | Promedicaments prostanoides lies a un support |
| SI3060041T1 (sl) | 2013-10-25 | 2021-04-30 | Insmed Incorporated | Spojine prostaciklina |
| EP3068438A1 (fr) | 2013-11-11 | 2016-09-21 | Ascendis Pharma Relaxin Division A/S | Promédicaments à bae de relaxine |
| EP3193941B1 (fr) | 2014-08-06 | 2024-05-22 | Ascendis Pharma A/S | Promédicaments comprenant un liant de type aminoalkylglycine |
| AU2015349969B2 (en) | 2014-11-18 | 2020-02-06 | Insmed Incorporated | Methods of manufacturing treprostinil and treprostinil derivative prodrugs |
| CN104458937B (zh) * | 2014-11-20 | 2017-02-22 | 北京京科泰来科技有限公司 | 一种丁酸氯维地平脂肪乳有关物质检测方法 |
| EP3303365A4 (fr) | 2015-05-29 | 2019-04-24 | Ascendis Pharma Inc. | Promédicaments comprenant un lieur de pyroglutamate |
| JP6949025B2 (ja) | 2015-12-17 | 2021-10-13 | ヤンセン ファーマシューティカ エヌ．ベー． | リスペリドンに対する抗体及びその使用 |
| SMT202600051T1 (it) | 2016-01-08 | 2026-03-09 | Ascendis Pharma Growth Disorders As | Agonisti del cnp a rilascio controllato con effetti collaterali ridotti |
| EP4162955A1 (fr) | 2016-01-08 | 2023-04-12 | Ascendis Pharma Growth Disorders A/S | Promédicaments du cnp ayant le transporteur fixé sur la partie cyclique du peptide |
| SG11201805026SA (en) | 2016-01-08 | 2018-07-30 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr-c binding |
| CN108472380B (zh) | 2016-01-08 | 2022-03-01 | 阿森迪斯药物生长障碍股份有限公司 | 具有增加的nep稳定性的控制释放cnp激动剂 |
| EP3400022A1 (fr) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Agonistes de cnp à libération contrôlée avec faible activité npr-b initiale |
| CA3007976C (fr) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Promedicaments du cnp possedant de grands fragments a role de transporteur |
| WO2018011266A1 (fr) | 2016-07-13 | 2018-01-18 | Ascendis Pharma A/S | Procédé de conjugaison pour promédicaments liés à un support |
| US20190204312A1 (en) * | 2016-09-16 | 2019-07-04 | Technische Universität München | Magnetic particle-binding peptides |
| LT3518930T (lt) | 2016-09-29 | 2023-05-10 | Ascendis Pharma Growth Disorders A/S | Kompleksinė terapija su kontroliuojamo išskyrimo cnp agonistais |
| CN106818805A (zh) * | 2016-12-27 | 2017-06-13 | 东莞市联洲知识产权运营管理有限公司 | 一种天然乙酰胆碱酯酶抑制剂及其杀虫应用 |
| AU2018309049A1 (en) * | 2017-08-04 | 2020-02-27 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of diabetes and related conditions |
| CA3106568A1 (fr) | 2018-07-19 | 2020-01-23 | Starpharma Pty Ltd | Dendrimere therapeutique |
| US12071517B2 (en) | 2018-07-19 | 2024-08-27 | Starpharma Pty Ltd. | Therapeutic dendrimer |
| WO2020087031A1 (fr) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa |
| EP3923906A1 (fr) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Formulations pharmaceutiques sèches de conjugués cnp |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| CA3138530A1 (fr) | 2019-04-29 | 2020-11-05 | Insmed Incorporated | Compositions de poudre seche de promedicaments de treprostinil et methodes d'utilisation de celles-ci |
| MX2021014830A (es) | 2019-06-21 | 2022-01-18 | Ascendis Pharma As | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. |
| EP3986471A1 (fr) | 2019-06-21 | 2022-04-27 | Ascendis Pharma A/S | Conjugués d'azote donneur d'électrons ou de composés comprenant une amine tertiaire |
| AU2020296297B2 (en) | 2019-06-21 | 2025-06-12 | Ascendis Pharma A/S | Conjugates of heteroaromatic nitrogen-comprising compounds |
| CN110652596B (zh) * | 2019-11-06 | 2020-11-03 | 吉林大学 | 一种雷公藤红素纳米粒子、其制备方法及应用 |
| US20230110994A1 (en) | 2020-01-03 | 2023-04-13 | Ascendis Pharma A/S | Conjugates undergoing intramolecular rearrangements |
| CA3184998A1 (fr) | 2020-08-05 | 2022-02-10 | Samuel WEISBROD | Conjugues comprenant des lieurs reversibles et leurs utilisations |
| JP2023542939A (ja) * | 2020-09-24 | 2023-10-12 | オキュラ セラピューティクス，インコーポレイテッド | ヒドロゲル及び活性薬剤を含む徐放性生分解性小管内挿入物 |
| BR112023004378A2 (pt) * | 2020-09-24 | 2023-04-04 | Ocular Therapeutix Inc | Insertos intracanaliculares biodegradáveis de liberação sustentada que compreendem um hidrogel e uma ciclosporina |
| JP2024514095A (ja) | 2021-04-01 | 2024-03-28 | アセンディス ファーマ エー／エス | 炎症によって誘発される疾患を治療するための長時間作用型成長ホルモンの使用 |
| CA3236278A1 (fr) | 2021-12-13 | 2023-06-22 | Kennett Sprogoe | Doses efficaces de conjugues cnp |
| CN119789847A (zh) | 2022-05-23 | 2025-04-08 | 阿森迪斯药物生长障碍股份有限公司 | Cnp化合物的液体药物制剂 |
| WO2024194300A1 (fr) | 2023-03-20 | 2024-09-26 | Ascendis Pharma Growth Disorders A/S | Méthode de traitement d'une déformation thoraco-lombaire chez un sujet humain atteint d'achondroplasie |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| WO2001062299A2 (fr) | 2000-02-28 | 2001-08-30 | Shearwater Corporation | Conjugues polymeres hydrosolubles d'acide artelinique |
| WO2002026867A2 (fr) * | 2000-09-29 | 2002-04-04 | The Regents Of The University Of California | Macromolécule transporteuse ou support dendrimère |
| EP1494757A2 (fr) | 2002-04-04 | 2005-01-12 | Enzon, Inc. | Derives acyles polymeriques d'indoles |
| AU2004228793B2 (en) | 2003-04-08 | 2009-10-08 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| BRPI0414017B8 (pt) | 2003-09-17 | 2021-05-25 | Nektar Therapeutics Al Corp | pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços. |
| WO2005099768A2 (fr) | 2004-03-23 | 2005-10-27 | Complex Biosystems Gmbh | Lieur de promedicaments |
| AT7634U1 (de) | 2004-06-29 | 2005-06-27 | Binder Co Ag | Detektiervorrichtung und sortiervorrichtung |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| KR20090083334A (ko) | 2006-09-15 | 2009-08-03 | 엔존 파마슈티컬즈, 인코포레이티드 | 방해된 에스테르 기재 생분해성 링커를 갖는 폴리알킬렌 옥시드 |
| HUE044174T2 (hu) | 2008-02-01 | 2019-10-28 | Ascendis Pharma As | Önhasítható linkert tartalmazó elõvegyület |
| WO2010019233A1 (fr) | 2008-08-11 | 2010-02-18 | Nektar Therapeutics | Conjugués d'alcanoate polymère à multiples bras |
| WO2010039861A2 (fr) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of Michigan | Conjugués de dendrimères |
| US20100158850A1 (en) | 2008-12-23 | 2010-06-24 | The Regents Of The University Of Michigan | Dendrimer based modular platforms |
| EP2459227B1 (fr) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Promédicaments contenant une amine aromatique liée à un support par liaison amide |
| WO2011012721A1 (fr) * | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Promédicaments de pramipexole liés à un support |
-
2012
- 2012-08-10 WO PCT/EP2012/065731 patent/WO2013024047A1/fr not_active Ceased
- 2012-08-10 EP EP12748192.7A patent/EP2741779A1/fr active Pending
- 2012-08-10 US US14/237,429 patent/US20140296257A1/en not_active Abandoned
- 2012-08-10 HK HK14112148.0A patent/HK1198629A1/xx unknown
- 2012-08-10 CA CA2843875A patent/CA2843875C/fr active Active
- 2012-08-10 AU AU2012296949A patent/AU2012296949B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1198629A1 (en) | 2015-05-22 |
| CA2843875C (fr) | 2020-01-07 |
| EP2741779A1 (fr) | 2014-06-18 |
| US20140296257A1 (en) | 2014-10-02 |
| WO2013024047A1 (fr) | 2013-02-21 |
| AU2012296949B2 (en) | 2016-09-15 |
| AU2012296949A1 (en) | 2014-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2843875C (fr) | Promedicaments lies a des excipients hydrosolubles de forte charge | |
| CA2843503C (fr) | Promedicaments lies a des excipients polymeriques hyperbranches | |
| US11559482B2 (en) | Biodegradable polyethylene glycol based water-insoluble hydrogels | |
| EP2741782B1 (fr) | Prodrogues liés à un support protéinique | |
| AU2014257745B2 (en) | Hydrogel-linked prodrugs releasing modified drugs | |
| US20230123784A1 (en) | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | |
| HK40045395A (en) | Biodegradable polyethylene glycol based water-insoluble hydrogels | |
| HK1198630B (en) | Protein carrier-linked prodrugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170530 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240730 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240730 |